These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22811823)

  • 21. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
    Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
    Chen Y; Perng RP; Yang KY; Lin WC; Wu HW; Tsai CM; Whang-Peng J
    Lung Cancer; 2000 Aug; 29(2):139-46. PubMed ID: 10963844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group.
    Ichinose Y; Yosimori K; Yoneda S; Kuba M; Kudoh S; Niitani H
    Cancer; 2000 Jan; 88(2):318-23. PubMed ID: 10640963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.
    Allegrini G; Falcone A; Di Marsico R; Lencioni M; Masi G; Galli C; Cupini S; Pfanner E; Marcucci L; Conte PF
    Am J Clin Oncol; 2004 Feb; 27(1):101-5. PubMed ID: 14758142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer.
    Lee WS; Lee KS; Kim KH; Ryoo BY; Kim WS; Kang WK; Kang YK; Heo DS; Bang YJ; Kim NK
    Cancer Res Treat; 2001 Jun; 33(3):225-8. PubMed ID: 26680789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
    Yang TS; Wang JY; Tang R; Hsu KC; Chen JS
    Jpn J Clin Oncol; 2002 Sep; 32(9):352-7. PubMed ID: 12417601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
    Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
    Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma.
    Mani S; Schiano T; Garcia JC; Ansari RH; Samuels B; Sciortino DF; Tembe S; Shulman KL; Baker A; Benner SE; Vokes EE
    Invest New Drugs; 1998-1999; 16(3):279-83. PubMed ID: 10360610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC).
    Saito J; Nakai Y; Saijo Y; Nukiwa T; Koinumaru S; Matsuura Y; Aso N; Yamane Y; Tsukamoto T; Sayama T; Nakabayashi T
    Lung Cancer; 2001; 31(2-3):285-93. PubMed ID: 11165409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Pharmacokinetics of Tegafur Administered with Epirubicin and Cisplatin in Patients with Advanced Gastric Cancer.
    Kang JH; Kim YL; Cho HK; Lee ES; Cha SJ; Hong YS; Lee KS; Kuh HJ
    Cancer Res Treat; 2003 Jun; 35(3):224-31. PubMed ID: 26680940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Park YT; Kim JG; Kim JS
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):119-23. PubMed ID: 9348583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
    Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.